BMS aims to parlay LAG3 approval into disruptive commercial strategy

After nearly a decade of searching for the next checkpoint target to follow PD-1, immuno-oncology marks a major milestone Friday with FDA’s approval of Bristol Myers’ LAG3 inhibitor Opdualag. And now BMS’s regulatory and commercial strategy for the therapy could shake up the checkpoint inhibitor market.

The approval also helps address the long-standing question of whether single-agent activity is a requirement for new cancer immunotherapy candidates — bolstering the case that it isn’t...